ArticleJournal of dental sciences2025
4'-hydroxywogonin inhibits oral squamous cell carcinoma progression by targeting Gas6/Axl signaling axis.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Oral squamous cell carcinoma (OSCC) is one of the most common head and neck malignancies, with current therapeutic strategies often limited by low efficacy and drug resistance. In this study, we investigated the anticancer potential and underlying mechanisms of 4'-hydroxywogonin, a flavonoid extracted from Scutellaria baicalensis, in OSCC. Materials and methods: OSCC cell lines were treated with 4'-hydroxywogonin, and its anticancer effects were evaluated using cell functional assays. Western blot analysis was performed to examine the regulatory pathways involved, and rescue assays were conducted to validate its mechanism of action. Results: 4'-Hydroxywogonin selectively inhibited OSCC cell proliferation, migration, and invasion without inducing cytotoxicity in normal human cells. Mechanistic studies revealed that 4'-hydroxywogonin downregulated Axl and its ligand Gas6, leading to the suppression of PI3K/AKT signaling, cell cycle checkpoint regulation, and epithelial-mesenchymal transition (EMT)-related proteins, ultimately inducing G1 phase cell cycle arrest and apoptosis. Moreover, the combination of 4'-hydroxywogonin with cisplatin significantly enhanced its inhibitory effects on OSCC. Conclusion: 4'-Hydroxywogonin exhibits potential as a novel therapeutic agent for OSCC, with the capacity to enhance cisplatin-mediated anticancer effects, highlighting its potential in combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.